Sagimet Biosciences Inc.
SGMT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.17 | 0.14 | -0.12 | -0.20 |
| FCF Yield | -4.57% | -3.71% | -13.85% | -7.61% |
| EV / EBITDA | -14.74 | -17.04 | -2.03 | -4.27 |
| Quality | ||||
| ROIC | -12.01% | -9.14% | -14.29% | -11.65% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 0.88 | 0.80 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -11.86% | 37.39% | -31.86% | 43.67% |
| Safety | ||||
| Net Debt / EBITDA | 2.51 | 3.54 | 3.26 | 4.68 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |